Evidence map›Paper›PMID 39519036›Full record

ReviewInternational journal of molecular sciences2024

Lessons from IgA Nephropathy Models.

Toshiki Kano, Hitoshi Suzuki, Yuko Makita, Yoshihito Nihei, Yusuke Fukao, Maiko Nakayama, Mingfeng Lee, Ryosuke Aoki, Koshi Yamada, Masahiro Muto and 1 more

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Toshiki KanoDepartment of Nephrology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan.
Hitoshi SuzukiDepartment of Nephrology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan.ORCID 0000-0002-1901-2111
Yuko MakitaDepartment of Nephrology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan.
Yoshihito NiheiDepartment of Nephrology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan.
Yusuke FukaoDepartment of Nephrology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan.ORCID 0000-0003-3846-8234
Maiko NakayamaDepartment of Nephrology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan.ORCID 0000-0002-2818-5081
Mingfeng LeeDepartment of Nephrology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan.
Ryosuke AokiDepartment of Nephrology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan.
Koshi YamadaDepartment of Nephrology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan.
Masahiro MutoDepartment of Nephrology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan.
Yusuke SuzukiDepartment of Nephrology, Juntendo University Faculty of Medicine, Tokyo 113-8421, Japan.

Funding

Japan Society for the Promotion of Science JP22K16226
6 · The paper itself

Abstract

IgA nephropathy (IgAN) is the most common type of primary glomerulonephritis worldwide; however, the underlying mechanisms of this disease are not fully understood. This review explores several animal models that provide insights into IgAN pathogenesis, emphasizing the roles of aberrant IgA1 glycosylation and immune complex formation. It discusses spontaneous, immunization, and transgenic models illustrating unique aspects of IgAN development and progression. The animal models, represented by the grouped ddY (gddY) mouse, have provided guidance concerning the multi-hit pathogenesis of IgAN. In this paradigm, genetic and environmental factors, including the dysregulation of the mucosal immune system, lead to increased levels of aberrantly glycosylated IgA, nephritogenic immune complex formation, and subsequent glomerular deposition, followed by mesangial cell activation and injury. Additionally, this review considers the implications of clinical trials targeting molecular pathways influenced by IgAN (e.g., a proliferation-inducing ligand [APRIL]). Collectively, these animal models have expanded the understanding of IgAN pathogenesis while facilitating the development of therapeutic strategies that are currently under clinical investigation. Animal-model-based studies have the potential to facilitate the development of targeted therapies with reduced side effects for IgAN patients.

Indexed as

Disease Models, AnimalGlomerulonephritis, IGAImmunoglobulin AAnimalsGlycosylationHumansMiceImmunoglobulin Aanimal modelsAPRIL (a proliferation-inducing ligand)endothelingalactose deficient IgA1IgA nephropathyimmune complexToll-like receptors

Identifiers

PMID39519036
PMCPMC11546737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.